Lingsheng Medical and China Resources Sanjiu Announce Strategic Cooperation Agreement to Accelerate Overseas Innovative Drug Commercialization in China

Original Title: Link Health Pharma andCR SANJIUPharmaceutical Companies Reach Strategic Cooperation Intent Source: Shenzhen Ruixiangyuan

Recently, Guangzhou Link Health Pharma Co., Ltd. (hereinafter referred to as "Link Health Pharma") and CR SANJIU (hereinafter referred to as "CR SANJIU") reached a strategic cooperation intention. The two parties intend to reach a package cooperation agreement on the introduction of production and sales of new drugs from abroad.

Since its establishment, Link Health Pharma has been dedicated to the introduction and research and development of new drug projects. Within just five years, it has successfully advanced one new drug marketing application and five Investigational New Drug (IND) applications. CR SANJIU, on the other hand, specializes in Good Manufacturing Practice (GMP) production and multi-brand marketing of pharmaceuticals. Through this collaboration, both parties will leverage their complementary strengths to accelerate the domestic launch and sales of innovative overseas pharmaceutical products, thereby meeting the clinical needs of patients in China more effectively and efficiently.

About Link Health Pharma:

Link Health Pharma has been committed to accelerating new drug development through international collaboration and independent R&D since its establishment, always prioritizing the clinical needs of patients in China. The company’s current R&D pipeline comprises 12 innovative drug candidates, with indications spanning various therapeutic areas, including oncology and chronic diseases. Multiple projects have advanced into Phase I and Phase II clinical trials, and some have reached the stage of filing for New Drug Application (NDA).

About CR SANJIU:

CR SANJIU is a large state-owned pharmaceutical listed company, focusing on the research and development, production, sales of pharmaceutical products, as well as other health-related services. Adhering to the mission of "Caring for Public Health, Co-creating a Better Life," it innovatively applies Chinese and Western medical science and technology. While concentrating on the innovative R&D and intelligent manufacturing of high-quality pharmaceutical and healthcare products, it actively introduces premium brands and products through various channels.

About Us

Shenzhen Ruixiangyuan Fund Management Co., Ltd. is a professional equity investment institution focused on the biopharmaceutical and healthcare sector, with investments spanning all stages from angel investing, venture capital (VC), and private equity (PE) to industrial M&A. The company boasts a professional healthcare investment team comprising multiple MDs and PhDs in medicine and pharmacy, and is committed to becoming a renowned healthcare investment institution both domestically and internationally. Its current investment focus primarily lies in niche sectors such as innovative and high-end generic drugs, high-end medical devices and related components, and technology-driven healthcare services, with business operations extending across multiple countries including China, the United States, Canada, and Israel.

Over the past few years, the company’s investment team has reviewed more than 2,000 healthcare projects, conducted on-site due diligence for over 100 companies, invested in nearly 20 projects, and built a substantial pipeline of high-quality opportunities. We firmly believe that by adhering to international capital operation concepts and strategies, and through deep specialization in our field, we can maximize value creation for both investors and project partners.